Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4702 - Neoadjuvant Systemic Chemotherapy prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the treatment of Peritoneal Carcinomatosis from Colorectal Cancer


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Surgical Oncology;  Radiation Oncology;  Colon and Rectal Cancer


Nethanel Asher


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


N. Asher1, G. Lahat2, R. Geva3

Author affiliations

  • 1 Medical Oncology, Tel Aviv Sourasky Medical Center-(Ichilov), 64239 - Tel Aviv/IL
  • 2 Surgical Oncology, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv/IL
  • 3 Research Unit, Division Of Oncology, Tel Aviv Sourasky Medical Center, 64239 - Tel Aviv/IL


Abstract 4702


Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) have become a standard treatment option for peritoneal carcinomatosis (PC) arising from colorectal carcinoma, despite the complexity and morbidity of this procedure. The timing of CRS+HIPEC in the course of the disease in unclear, and there is no consensus regarding pre-operative treatments. In this study we analyzed the effect of neoadjuvant systemic chemotherapy prior to CRS+HIPEC on patients' outcome.


Data on consecutive colorectal patients with PC, treated in the Sourasky Medical Center from Jan 2007 to Dec 2016 was collected. Demographic, pathologic and clinical data was registered for all patients. For patients treated with neoadjuvant chemotherapy, the regimen, duration and responses were recorded. Outcome measurements were postoperative complications, progression free survival (PFS) and overall survival (OS).


Seventy-two (72) patients were identified, of whom 43 (59.7%) were treated with neoadjuvant chemotherapy and 29 (40.3%) were referred directly to CRS+HIPEC. No significant demographic, pathological or clinical differences between the groups were found. Median PFS was 12 months in the Neo- group and 17 months in the Neo+ group (p = 0.015). On multivariate Cox-PH analysis, the effect of neoadjuvant chemotherapy on PFS was maintained (HR = 0.34, p = 0.002). Median OS was 41 months in the Neo- and 47 months in the Neo+ with no statistical difference. In the Neo+ group, on univariate analysis, there was no significant effect to chemotherapy regimen, duration of treatment, nor best response. There was no difference in postoperative complication rate between the groups.


In patients candidate for CRS+HIPEC for the treatment of PC from colorectal cancer, the administration of systemic neoadjuvant chemotherapy significantly prolongs PFS with no additional postoperative risks. Prospective randomized trials and larger patient cohorts are needed to confirm these findings and assess the effect on OS.

Clinical trial identification

Non Applicable

Legal entity responsible for the study

Tel Aviv University




R. Geva: Advisory board member: Bayer, MSD, Novartis. Honoraria: BMS, Lilly, Medison, Roche, Novartis, Janssen: Travel expenses: Roche, BMS All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.